Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy could not be established.

Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Wegovy is now positioned as the first and only GLP-1 treatment.

US FDA approves blockbuster weight loss drug for severe fatty liver disease: What this means for you?

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

Studies have found that semaglutide, the chemical in Ozempic, reduced alcohol intake, binge drinking and relapse ...

Andersen has a fair value estimate of $71 for Novo stock. Closing around $52.41 on Aug. 15 (near its lowest level since ...

The FDA has granted accelerated approval for Wegovy for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults.

FDA has approved Novo Nordisk's Wegovy, one-weekly 2.4 mg semaglutide injection for treating metabolic-associated ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...